A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention.

DUNNILL, Christopher John, AL-TAMEEMI, Wafaa, COLLETT, Andrew, HASLAM, Iain Stuart and GEORGOPOULOS, Nikolaos Theodoros (2017). A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention. The Oncologist, 23 (1), 84-96.

Preview

PDF Georgopoulos-ClinicalAndBiological(AM).pdf - Accepted Version All rights reserved. Download (431kB) | Preview

Abstract

Chemotherapy-induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and self-esteem, it is important for clinicians to fully appreciate the psychological burden that CIA can place on patients. Here, for the first time to our knowledge, we provide a comprehensive review encompassing the molecular characteristics of the human hair follicle (HF), how different anticancer agents damage the HF to cause CIA, and subsequent HF pathophysiology, and we assess known and emerging prevention modalities that have aimed to reduce or prevent CIA. We argue that, at present, scalp cooling is the only safe and U.S. Food and Drug Administration-cleared modality available, and we highlight the extensive available clinical and experimental (biological) evidence for its efficacy. The likelihood of a patient that uses scalp cooling during chemotherapy maintaining enough hair to not require a wig is approximately 50%. This is despite different types of chemotherapy regimens, patient-specific differences, and possible lack of staff experience in effectively delivering scalp cooling. The increased use of scalp cooling and an understanding of how to deliver it most effectively to patients has enormous potential to ease the psychological burden of CIA, until other, more efficacious, equally safe treatments become available.

Implications for practice

Chemotherapy-induced alopecia (CIA) represents perhaps the most distressing side effect of chemotherapeutic agents and is of huge concern to the majority of patients. Scalp cooling is currently the only safe option to combat CIA. Clinical and biological evidence suggests improvements can be made, including efficacy in delivering adequately low temperature to the scalp and patient-specific cap design. The increased use of scalp cooling, an understanding of how to deliver it most effectively, and biological evidence-based approaches to improve its efficacy have enormous potential to ease the psychological burden of CIA, as this could lead to improvements in treatment and patient quality-of-life.

Item Type:	Article
Identification Number:	https://doi.org/10.1634/theoncologist.2017-0263
Page Range:	84-96
SWORD Depositor:	Symplectic Elements
Depositing User:	Symplectic Elements
Date Deposited:	08 Apr 2024 12:09
Last Modified:	08 Apr 2024 12:15
URI:	https://shura.shu.ac.uk/id/eprint/33181

Actions (login required)

View Item

Downloads

Publication Metrics